Get the Stockscreener App
11.95
2.28%
-0.345
Centessa Pharmaceuticals Plc Adr stock is traded at $11.95, with a volume of 342.85K.
It is down -2.28% in the last 24 hours and down -23.71% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
See More
Previous Close:
$12.29
Open:
$12.21
24h Volume:
342.85K
Relative Volume:
0.36
Market Cap:
$1.59B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-7.6603
EPS:
-1.56
Net Cash Flow:
$-160.51M
1W Performance:
+0.63%
1M Performance:
-23.71%
6M Performance:
-23.91%
1Y Performance:
+13.67%
1-Day Range:
$11.95
$12.40
1-Week Range:
$11.50
$12.81
52-Week Range:
$7.75
$19.09
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
11.96 | 1.59B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.33 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.77 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.39 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
229.65 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.23 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-25 | Initiated | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
Parsons Corp (PSN) Shares Up Despite Recent Market Volatility - News Heater
Lantheus Holdings Inc [LNTH] Insider Activity: An Update for Investors - knoxdaily.com
Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target - MarketScreener
Centessa Pharmaceuticals chief business officer sells $163,386 in stock - Investing.com
Centessa Pharmaceuticals CEO sells shares worth $918,060 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CEO sells shares worth $918,060 - Investing.com India
Centessa Pharmaceuticals CAO sells shares worth $120,205 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CAO sells shares worth $120,205 - Investing.com India
Centessa Pharmaceuticals’ general counsel sells $98,697 in stock - Investing.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - Stocks Register
Ratios Revealed: Decoding Centessa Pharmaceuticals plc ADR (CNTA)’s Financial Health - The Dwinnex
Hemophilia Market Insights: Key Trends and Developments Across Different Types of Hemophilia | DelveInsight - GlobeNewswire Inc.
Centessa Pharmaceuticals officer sells shares worth $588,943 - Investing.com India
Aegon Ltd (AEG) looking to reclaim success with recent performance - SETE News
Adversity is less terrifying than hope: Wayfair Inc (W) - SETE News
Perhaps timely catching Autolus Therapeutics plc ADR (AUTL) would be a good idea - SETE News
Taking the lead: Centessa Pharmaceuticals plc ADR (CNTA) - SETE News
Centessa Pharmaceuticals plc ADR (CNTA) Volatility Hits 6.67%: What Good Investors Need To Be Aware Of - Stocks Register
RLI Corp’s (RLI) Stock: A Week-by-Week Analysis - The News Heater
Centessa Pharmaceuticals plc ADR (CNTA) Shares Up Despite Recent Market Volatility - The News Heater
Aon plc (AON) Stock: Evaluating the Market Performance - The News Heater
Qudian Inc ADR (QD) Stock: A Look at the Analyst Recommendations - The News Heater
Examining the Volatility of Costamare Inc’s (CMRE) Stock - The News Heater
Centessa Pharmaceuticals officer Tia Bush sells $185,406 in shares - Investing.com
Financial Fitness Check: Examining Magna International Inc (MGA)’s Key Ratios - The Dwinnex
Financial Metrics Exploration: Understanding Oncolytics Biotech, Inc (ONCY) Through Ratios - The Dwinnex
Financial Health Report: EyePoint Pharmaceuticals Inc (EYPT)’s Ratios Tell a Tale - The Dwinnex
A closer look at Centessa Pharmaceuticals plc ADR (CNTA) is warranted - US Post News
Centessa Pharmaceuticals chief business officer sells shares worth $193,429 - Investing.com India
Form N-CSR FIDELITY CONCORD STREET For: Nov 30 - StreetInsider.com
Centessa Pharmaceuticals general counsel Hussain Iqbal sells $91,740 in shares - Investing.com
Centessa Pharmaceuticals appoints new Chief Medical Officer - Investing.com
Centessa Pharmaceuticals' chief business officer sells shares worth $170,399 - Investing.com
Centessa Pharmaceuticals CEO sells $959,057 in shares - Investing.com India
Centessa Pharmaceuticals general counsel sells shares for $1.27 million By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals general counsel sells shares for $1.27 million - Investing.com
Stock Market Recap: Tencent Music Entertainment Group ADR (TME) Concludes at 11.30, a -5.68 Surge/Decline - The Dwinnex
Banzai International Inc (NASDAQ: BNZI): Getting A Free Pass? - Stocks Register
Metrics That Matter About Credo Technology Group Holding Ltd (NASDAQ: CRDO) - Stocks Register
Centessa Pharmaceuticals stock hits 52-week high at $18.77 By Investing.com - Investing.com UK
Centessa Pharmaceuticals CEO Saha Saurabh sells $5,450 in shares - Investing.com India
Centessa Pharmaceuticals' chief business officer sells $176,601 in shares - Investing.com
Centessa Pharmaceuticals CEO Saurabh sells shares worth $1.02 million - Investing.com India
Centessa Pharmaceuticals CEO Saurabh sells shares worth $1.02 million By Investing.com - Investing.com South Africa
Deutsche Bank initates Fidelity National Financial Inc (FNF) stock to a Hold - Knox Daily
Centessa Pharmaceuticals CEO sells shares worth $585,418 - Investing.com India
Endava PLC Sponsored ADR (DAVA) Beats Q1 Earnings Estimates - Yahoo Finance
XPeng Inc. Sponsored ADR (XPEV) Stock Moves -1.06%: What You Should Know - Yahoo Finance
Centessa Pharmaceuticals' chief business officer sells shares for $180,628 - Investing.com
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last? - Yahoo Finance
Centessa Pharmaceuticals plcADR (CNTA) Price Target Increased by 14.58% to 11.22 - MSN
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):